Reduction in visible surface area of the lipoma 6 months post injection [clinicaltrials_resource:16f8a919cfdf03dd0bf1ff9049f5bac9]
The primary efficacy outcome is lipoma visible surface area defined as the longest dimension ("length") times the longest dimension perpendicular to length ("width"). Visible surface area will be analyzed as the percent change from baseline at the 6-month visit.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Reduction in visible surface area of the lipoma 6 months post injection [clinicaltrials_resource:16f8a919cfdf03dd0bf1ff9049f5bac9]
The primary efficacy outcome is lipoma visible surface area defined as the longest dimension ("length") times the longest dimension perpendicular to length ("width"). Visible surface area will be analyzed as the percent change from baseline at the 6-month visit.
Bio2RDF identifier
16f8a919cfdf03dd0bf1ff9049f5bac9
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:16f8a919cfdf03dd0bf1ff9049f5bac9
measure [clinicaltrials_vocabulary:measure]
Reduction in visible surface area of the lipoma
time frame [clinicaltrials_vocabulary:time-frame]
6 months post injection
description
The primary efficacy outcome i ...... baseline at the 6-month visit.
identifier
clinicaltrials_resource:16f8a919cfdf03dd0bf1ff9049f5bac9
title
Reduction in visible surface area of the lipoma 6 months post injection
@en
type
label
Reduction in visible surface a ...... 8a919cfdf03dd0bf1ff9049f5bac9]
@en